Open questions and future priorities with novel agents in primary eosinophilic neoplasms
| • Need for response criteria for MLN with eosinophilia and tyrosine kinase gene fusions |
| • Increasing diagnostic recognition of MLN with eosinophilia and tyrosine kinase gene fusions given the availability of targeted therapies |
| • How do we incorporate standard cytogenetic/FISH and molecular monitoring of tyrosine kinase fusion genes into clinical decision-making? |
| • Harmonization of molecular monitoring techniques for tyrosine kinase fusion genes |
| • What is the optimal induction and maintenance dosing of tyrosine kinase inhibitors in specific MLN with eosinophilia and tyrosine kinase gene fusions? |
| • What are the best predictors of treatment-free remission in PDGFRA- and PDGFRB-rearranged MLN treated with imatinib? |
| • In FGFR1-rearranged MLN, is pemigatinib monotherapy sufficient for chronic phase disease, and what is the role of lineage-specific induction chemotherapy ± pemigatinib in blast phase disease? |
| • How do we incorporate small-molecule inhibitors of MLN tyrosine kinase gene fusions as a cytoreduction strategy before transplant? |
| • What is the role of pemigatinib and other tyrosine kinase inhibitors posttransplant to minimize disease relapse? |
| • Unmet therapeutic need in CEL: evaluate HMAs and other therapies (eg, venetoclax) in the context of clinical trials |
| • Need for response criteria for MLN with eosinophilia and tyrosine kinase gene fusions |
| • Increasing diagnostic recognition of MLN with eosinophilia and tyrosine kinase gene fusions given the availability of targeted therapies |
| • How do we incorporate standard cytogenetic/FISH and molecular monitoring of tyrosine kinase fusion genes into clinical decision-making? |
| • Harmonization of molecular monitoring techniques for tyrosine kinase fusion genes |
| • What is the optimal induction and maintenance dosing of tyrosine kinase inhibitors in specific MLN with eosinophilia and tyrosine kinase gene fusions? |
| • What are the best predictors of treatment-free remission in PDGFRA- and PDGFRB-rearranged MLN treated with imatinib? |
| • In FGFR1-rearranged MLN, is pemigatinib monotherapy sufficient for chronic phase disease, and what is the role of lineage-specific induction chemotherapy ± pemigatinib in blast phase disease? |
| • How do we incorporate small-molecule inhibitors of MLN tyrosine kinase gene fusions as a cytoreduction strategy before transplant? |
| • What is the role of pemigatinib and other tyrosine kinase inhibitors posttransplant to minimize disease relapse? |
| • Unmet therapeutic need in CEL: evaluate HMAs and other therapies (eg, venetoclax) in the context of clinical trials |